Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
Tuesday, December 10, 2024Krystal Biotech Inc a commercialstage biotechnology company today announced that the European Medicines Agencys EMAs Committee for Medicinal Products for Human Use CHMP cancelled the Oral Explanation regarding the Companys Marketing Authorization App...
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Tuesday, December 10, 2024Lantern Pharma Inc an artificial intelligence AI company developing targeted cancer therapies using its proprietary RADR AI platform today announced that the first patient has been enrolled and dosed in Taiwan for its Phase HARMONIC clinical trial e...
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Monday, December 09, 2024Datopotamab deruxtecan DatoDXd has been granted Breakthrough Therapy Designation BTD in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptormutated EGFRm nonsmall cell lung cancer NSCLC with...
DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
Monday, December 09, 2024JanssenCilag International NV a Johnson Johnson company announced data highlighting that DARZALEX daratumumab subcutaneous SCbased regimens improve overall and sustained minimal residual disease MRD negativity rates and progressionfree survival PFS...
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Friday, December 06, 2024Hansa Biopharma Hansa announced it has completed the enrolment of patients in the GOODIDES trial a global pivotal Phase trial in antiglomerular basement membrane antiGBM disease AntiGBM is a rare severe autoimmune condition affecting around people...
Ep Dualfilter T.I.P.S.® - Effective Protection from Bio-Aerosols
Friday, December 06, 2024Bioaerosols arent welcome in any laboratory They can consist of bacteria cell fragments fungal spores or viruses as well as byproducts of microbial metabolism Aerosols are easily generated in various concentrations during simple routine tasks in the...
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Thursday, December 05, 2024Roche announced today that the US Food and Drug Administration FDA has accepted the companys supplemental Biologics License Application sBLA for Columvi glofitamab in combination with gemcitabine and oxaliplatin GemOx for the treatment of people with...
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
Wednesday, December 04, 2024Novo Nordisk today announced the presentation of abstracts three of which will be presented in oral sessions at the upcoming th Annual Meeting and Exposition of the American Society of Hematology ASH which will take place from to December in San...
Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development
Wednesday, December 04, 2024Amarna Therapeutics a privately held biotechnology company specializing in transformative gene therapies is pleased to announce its strategic collaboration with NorthX Biologics a leading biologics manufacturing partner This partnership represents a...
AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency
Wednesday, December 04, 2024AlveoGene a company focused on transforming rare respiratory disease outcomes using inhaled gene therapy announces that the US Food Drug Administration FDA has granted Orphan Drug Designation ODD to AVG the Companys novel inhaled gene therapy for le...
